All In MedTech

Device Trial Radar · NCT04076566

Malignant Ascites Alfapump® Study

Prospective Study in the Use of the Alfapump® in the Treatment of Malignant Ascites

Last checked: Nov 19, 2026Latest source record: Aug 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 31, 2020

Primary completion

Dec 2021

Study completion Mar 2022

Sponsor

Lead sponsor
Sequana Medical N.V.Not on our public-company list
Sponsor type
Industry
First posted
Sep 3, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

ProMAS is a prospective post-marketing, single-arm study to assess performance and safety of the Alfapump® system in the treatment of patients with malignant ascites. The study aims to enroll 40 patients in up to 8 sites in Europe.

Conditions

  • Malignant Ascites

Interventions

  • alfapump systemDevice

    active implantable device for treatment of malignant ascites

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monthly therapeutic paracentesis frequency up to 3 monthsTime frame: 3 months post-implantation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hammersmith Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.